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Rhinovirus infections are the most common cause of viral illness in humans, and there is increasing evidence of
their etiological role in severe acute respiratory tract infections (ARTIs). Human rhinoviruses (HRVs) are classified
into two species, species A and B, which contain over 100 serotypes, and a recently discovered genetically hetero-
geneous third species (HRV species C). To investigate their diversity and population turnover, screening for the
detection and the genetic characterization of HRV variants in diagnostic respiratory samples was performed by
using nested primers for the efficient amplification of the VP4-VP2 region of HRV (and enterovirus) species and
serotype identification. HRV species A, B, and C variants were detected in 14%, 1.8%, and 6.8%, respectively, of 456
diagnostic respiratory samples from 345 subjects (6 samples also contained enteroviruses), predominantly among
children under age 10 years. HRV species A and B variants were remarkably heterogeneous, with 22 and 6 different
serotypes, respectively, detected among 73 positive samples. Similarly, by using a pairwise distance threshold of 0.1,
species C variants occurring worldwide were provisionally assigned to 47 different types, of which 15 were present
among samples from Edinburgh, United Kingdom. There was a rapid turnover of variants, with only 5 of 43
serotypes detected during both sampling periods. By using divergence thresholds and phylogenetic analysis, several
species A and C variants could provisionally be assigned to new types. An initial investigation of the clinical
differences between rhinovirus species found HRV species C to be nearly twice as frequently associated with ARTIs
than other rhinovirus species, which matches the frequencies of detection of respiratory syncytial virus. The study
demonstrates the extraordinary genetic diversity of HRVs, their rapid population turnover, and their extensive
involvement in childhood respiratory disease.
Human rhinoviruses (HRVs) have recently been classified in
the genus Enterovirus, family Picornaviridae (34). Typically for
picornaviruses, they are small, nonenveloped, single-stranded
positive-sense viruses with a 7,200-base mRNA genome.
HRVs are highly heterogeneous genetically and antigenically.
A total of 101 serotypes have been classified, and these fall into
two species, HRV species A (HRV-A; 74 serotypes) and
HRV-B (25 serotypes); HRV serotype 87 is genetically most
similar to members of human enterovirus (HEV) species D
(HEV-D). Recently, several reports have described the detec-
tion and characterization of a series of new divergent rhinovi-
rus variants that have provisionally been assigned to a new
species, HRV-A2 or HRV-C (1, 13, 15, 16, 18, 22, 28).
HRVs are the most common etiological agents of upper
respiratory tract infections and regularly cause a mild, self-
limiting illness that is often referred to as the common cold.
HRV infections are transmitted most commonly by the respi-
ratory-salivary route, both by person-to-person contact and by
airborne transmission. In temperate countries, infections occur
primarily in two peaks, with the first being in April and May
and the second being in September and October (24, 38). HRV
infections occur in all age groups during all seasons, with a
90% past infection frequency by the age of 2 years (2). While
infections are frequently associated with mild upper respira-
tory tract symptoms, HRV infections have been implicated in
more serious illnesses, including pneumonia, otitis media, ex-
acerbations of asthma, and chronic obstructive pulmonary dis-
ease (for a review, see reference 20). Whether HRV-C is more
likely to be etiologically associated with the more severe end of
the HRV-associated spectrum of respiratory disease is cur-
rently under active debate and investigation (23, 40).
In the study described here, we have coupled a sensitive
PCR-based method for screening for HRV using primers from
the conserved 5 untranslated region (UTR) with a VP4-VP2
amplification and typing method that can be applied directly to
clinical specimens. The method effectively amplifies and allows
the genetic characterization of all three species of HRV as well
as HEVs. When the method was applied to respiratory speci-
mens collected in Edinburgh, United Kingdom, we were able
to document the diversity and rapid turnover of circulating
HRV strains, including species C variants, in a predominantly
pediatric population.
MATERIALS AND METHODS
Study population and samples. A total of 456 respiratory samples from 345
patients (189 male patients, 155 female patients, 1 patient whose sex was un-
known) referred to the Specialist Virology Centre, Royal Infirmary of Edin-
burgh, for testing for respiratory virus infection in September 2006 and February
2007 were used in this study. The samples predominantly comprised nasopha-
ryngeal aspirates or swabs (n  397; 87%) and were routinely screened for the
following respiratory viruses by previously described PCR assays (8, 37): adeno-
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virus (AdV), influenza A and B viruses, parainfluenza virus type 1 (PIV-1),
PIV-2, PIV-3, and respiratory syncytial virus (RSV). The samples were further
tested for human parechovirus (7) and human metapneumovirus (5a). The sam-
ples referred were predominantly from hospital inpatients or patients in accident
and emergency departments; only seven samples were sent from outpatient
attendees, and three were sent from general practitioners.
All samples were anonymously labeled and deposited in the Specialist Virol-
ogy Centre respiratory sample archive before they were tested. Approval was
obtained from the Lothian Regional Ethics Committee (approval number 08/
S11/02/2) to retain the collected information for epidemiological purposes but to
make the information anonymous to strictly protect patient confidentiality. The
stored data included age band, partial postcode, any recorded symptoms or
clinical information, referral source, month of sample collection, and the results
of other virological tests for each sample.
HRV and HEV detection. RNA was extracted from 100 l of the clinical
specimens by using a MinElute virus spin kit, according to the manufacturer’s
instructions (Qiagen, Hemel Hempstead, United Kingdom), and the extracted
RNA was stored at 70°C. RNA from pools or individual samples was reverse
transcribed into cDNA by using a reverse transcription system (Promega, United
Kingdom), according to the manufacturers’ instructions, and by using the
changes described previously (7). Amplification of the 5 UTR, the VP4-VP2
region, and the VP1 region of the genome used a previously described nested
RT-PCR strategy (7) and the primers listed in Table 1; the three HEV- and
HRV-specific 5 UTR inner sense primers were included in the second ampli-
fication step. For a small number of samples that were positive with the 5 UTR
primers but negative for VP4-VP2 amplification, SuperScript III (Invitrogen)
was used for reverse transcription before amplification with the VP4-VP2 prim-
ers (19). The amplification products were visualized by gel electrophoresis.
Screening of individual samples was accomplished with primers targeting the
highly conserved 5 UTR of the genome. The sensitivity of the assay using the
combined inner primers for the detection of HEV was assessed by comparison of
the results with those obtained by a previously described procedure (19). The
VP4 region and part of the VP2 genome region (VP4-VP2) of samples positive
with the 5 UTR-specific primers were subsequently amplified. VP4-VP2 was
sequenced and subjected to phylogenetic analysis, as were published full-length
and overlapping partial sequences from VP4-VP2; the previously published full-
length sequences predominantly comprised those from HRV reference strains
whose serotypes were previously determined by serological methods (14, 25, 36).
The VP1 region of reference strains whose sequences were not clearly grouped
with previously designated HRV serotypes was amplified and sequenced. The
edited sequences generated from this study were aligned with published se-
quences by using the Simmonics sequence editor (version 1.6) program (33;
http://www.virus-evolution.org/). Phylogenetic trees were constructed by neigh-
bor joining from 100 samplings of maximum-composite-likelihood distances by
using the MEGA (version 4.0) software package (35) with pairwise deletion for
missing data.
Nucleotide sequence accession numbers. The sequences generated in this
study have been assigned GenBank accession numbers GQ476576 to GQ476685.
RESULTS
Sample screening and serotype identification. Primers for
amplification of the 5 UTR were newly designed to accom-
modate the sequence variability within the much larger data set
of published sequences of all HRV-A and HRV-B serotypes,
along with the sequences obtained from the recently described
species C variants. Conserved regions between HRV-A, -B,
and -C coincided with those of HEV-A to HEV-D, enabling a
combined HRV-HEV amplification method, although the in-
corporation of HEV and HRV-C amplification necessitated
the use of separate inner sense primers; for example, HEV 5
UTR sequences differed from HRV at several positions in the
primer-binding target (Table 1; the bases that are different are
underlined and in boldface). The sensitivity of the combined
HEV-HRV PCR was compared to that of a previously de-
scribed 5 UTR-based nested PCR previously used for the
screening of clinical specimens (cerebrospinal fluid in sus-
pected viral meningitis/encephalitis cases [19]) and surveil-
lance samples (blood donor screening [39]) (Table 2). On the
basis of the proportion of replicates positive at each dilution,
the two assays showed identical sensitivities.
To investigate the frequency and the genetic diversity of
HRV and HEV strains among respiratory samples referred for
diagnostic testing, a total of 456 samples were collected from
345 study subjects in September 2006 (n  136) and February
2007 (n  320). High detection frequencies were observed in
both months (51 of 136 [38%] samples in 2006 and 60 of 320
TABLE 1. Primers used for amplification of HRV and HEV 5 UTR and VP4-VP2 regions and VP1 of HRV-A
Region Target Orientationa Positionb Sequencec
5 UTR HRV and HEV OS 178 HCAAGYACTTCTGTYWCCCCSG
HRV and HEV OAS 573 GAAACACGGACACCCAAAGTAGT
HRV-A and HRV-B IS 367 CYAGCCTGCGTGGCKGCCWRC
HRV-C IS 367 GTAGCCYGCGTGGTGCCCWGC
HEV IS 370 GGCTGCGYTGGCGGCCTRC
HRV and HEV IAS 477 TTAGCCRCATTCAGGGGCCGG
VP4-VP2 HRV and HEV OS 458 CCGGCCCCTGAATGYGGCTAA
HRV and HEV IS 547 ACCRACTACTTTGGGTGTCCGTG
HRV and HEV IAS 1087 TCWGGHARYTTCCAMCACCANCC
HRV and HEV OAS 1125 ACATRTTYTSNCCAAANAYDCCCAT
VP1 HRV-A OS 1995 MGHTTYAGYTTYATGTTYTGTGG
HRV-A IS 2430 TRGAYGCWGCWGARACWGG
HRV-A IAS 3333 GTRTTTGTKCGGTADATGAYTARRTC
HRV-A OAS 3525 CCACARTCWCCWGGYTCACADGG
a Abbreviations: OS, outer sense; OAS, outer antisense; IS, inner sense; IAS, inner antisense.
b The 5 base position numbered according to the HRV-B serotype 14 genome (GenBank accession number NC_001490).
c Primer positions that differ between HEV, HRV-A, HRV-B, or HRV-C are indicated in underlined boldface.
TABLE 2. Sensitivity of HRV-HEV combined PCR assay
Assaya
Result for the following control dilutionb:
101 102 103 104 105 106
HRV and HEV 2/2 4/4 8/8 15/16 8/16 1/11
HEV 2/2 4/4 8/8 16/16 7/16 0/16
a HRV-HEV, combined assays used for sample screening; HEV, previously
described HEV assays (39).
b Test dilution of previously described dilution standard (echovirus virus 30
19). The results represent the number of samples positive/total number of
samples tested.
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[19%] samples in 2007). To identify the infecting serotypes, the
more variable, longer, and more phylogenetically informative
VP4-VP2 region of each positive sample was amplified and
sequenced. Of the 111 5 UTR-positive samples, the VP4-VP2
regions of 110 could be amplified and sequenced (Fig. 1). The
single exception was a follow-up sample from a subject with a
previous VP4-VP2-positive sample.
For sequences grouping with the HRV-A and the HRV-B
clades, serotype assignments were performed by recording the
nearest neighbors among the published sequences of serologically
defined HRV reference sequences (29) (Table 3). This approach
was used because distance thresholds (either nucleotide or amino
acid sequences) between serotypes currently remain undeter-
mined, although this issue is investigated below in relation to the
putative type assignments for species C variants.
By using the existing nearest-neighbor assignment method,
nine subjects were found to be infected with two different
HRV-A variants with no single closest neighbor (Fig. 1), and
these variants were genetically divergent from all other sero-
types. The VP4-VP2 sequence of new serotype 1 (NS1) dif-
fered from that of the closest prototype isolate (serotype A46)
by 17.6%, while the VP4-VP2 sequence of NS2 differed from
that of its closest neighbor (serotype A77) by 14.0%. To inves-
tigate whether these variants were similarly divergent else-
where in the genome, the sequences of the VP1 region were
compared by amplification with a new set of nested primers
spanning nucleotide positions 2516 to 3285 (Fig. 2). The phy-
logeny relationships between the most closely grouping se-
quences in VP4-VP2 were similar to those of the most closely
grouping sequences in the VP1 region; the lack of nearest
neighbors and the high degree of sequence divergence in the
second genomic region (VP1) provide evidence for the exis-
tence of two new serotypes of HRV-A. The inclusion of pub-
lished VP4-VP2 sequences derived from a previous PCR-
based screening of clinical specimens revealed that viruses
similar to NS1 were present in samples from other surveys (see
Discussion). No sequences in the GenBank database were sim-
ilar to NS2.
Variants of HRV-C are not currently assigned to serotypes,
as methods for their in vitro culture have not been successful to
date and their cross-neutralization properties remain un-
known. However, variants within the species fell into a number
of separate branches or groups that showed pairwise distances
equal to or greater than those between the serotypes of other
HRV species. To investigate whether assignment on the basis
of a distance threshold was feasible, the frequency distributions
of the pairwise distances between the 184 VP4-VP2 sequences
available in the GenBank database (as of 12 May 2009) of
species C variants were compared with those of species A (n 
447) and species B (n  141) (Fig. 3).
FIG. 1. Diversity of HRV variants detected in the study. The phylogeny of the VP4-VP2 sequences amplified from strains from the study
subjects and the results of a comparison of those sequences with those from reference strains of species A and B or with other published sequences
from species C of currently unassigned types are shown (for clarity, sequences showing less than 0.5% divergence in the analyzed region were
excluded from the tree). For phylogeny estimation, neighbor-joining trees were constructed by using maximum-composite-likelihood distances
estimated between sequences in the amplified region (positions 629 to 1063 numbered according to the HRV-B14 reference sequence [GenBank
accession number NC_001490]). Data were bootstrap resampled 100 times to assess the robustness of the branches; values of 70% or greater are
shown. All trees were drawn to the same scale; for species A and C variants, HRV-B (GenBank accession number NC_001490) was used to root
the trees; sequence HRVACG (serotype 1B; GenBank accession number D00329) was used to root the species B tree.
TABLE 3. HRV serotypes detected among study subjects
Species and serotype
No. of samples with the indicated
serotype in:
September
2006
February
2007
Species A
A9 2
A12 1 2
A34 1
A41 1
A29/A44 2
A49 1
A55 2
A56 3 1
A57 1
A89 9
NS1a 8
A22 2
A28 6
A33 1
A59 5
A67 1
A75 1
A78 11
A85 1
A90 1
A95 1
NS2a 1
Total (n  22) 31 34
Species B
B4 1
B52 2
B84 1
B27 1 1
B6 1
B72 1
Subtotal (n  6) 5 3
Species Cb
C1 1
C5 2
C9 2
C10 1 2
C11 3 1
C2 1
C3 1
C4 1
C6 1
C7 4
C8 2
C12 3
C13 4
C14 1
C15 1
Subtotal (n  15) 9 22
a Provisionally assigned new HRV-A serotypes.
b Temporary names based on tree position.
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For the species A and B variants, the distinction between in-
tratype pairwise distances and between serotype pairwise dis-
tances was assisted by the inclusion of reference sequences of
assigned serotypes, allowing the distributions of the interpairwise
distances (Fig. 3, light gray bars) and the intrapairwise distances
(Fig. 3, dark gray bars) to be identified. For both species, the
pairwise distances fell to a minimum value at sequence divergence
values of approximately 11% (HRV-A) and 10% (HRV-B). The
only exceptions to these serotype assignment thresholds were
distances between eight species A serotype pairs (serotype 25-
FIG. 2. VP4-VP2 and VP1 phylogenies of putative new serotypes and the most closely related HRV-A serotypes. A comparison of the
phylogenies in the VP4-VP2 and VP1 regions of the putative new serotypes, NS1 and NS2, and the most closely related HRV-A serotypes is shown.
The symbols correspond to those used in Fig. 1.
0 0.1 0.2 0.3 0.40 0.1 0.2 0.3 0.4 0 0.1 0.2 0.3 0.4
Species A Species B Species C
Nucleode sequence divergence (uncorrected p distance)
Max. 0.1143 Min. 0.1103 Max. 0.1057 Min. 0.1034
FIG. 3. Pairwise distances between and within HRV-A and HRV-B serotypes and identification of the divergence threshold in species C. The
distributions of the pairwise distances between the available VP4-VP2 sequences (between positions 629 and 958) of HRV-A (n  447), HRV-B
(n  141), and HRV-C (n  220) variants are shown (sequences were downloaded from the GenBank database on 12 May 2009). The inter- and
intraserotype (shaded light and dark gray, respectively) distance ranges for species A and B were calculated by using reference sequences of
assigned serotypes (14, 25, 29, 36). The dotted line shows the upper limit of the intraspecies divergence in HRV-A and HRV-B and a provisionally
assigned threshold of 0.1 for the currently unclassified HRV-C variants. For all three species, the y-axis scale for intraserotype comparisons
(inferred in the case of HRV-C) was expanded fivefold for clarity.
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serotype 62, serotype 29-serotype 44, serotype 8-serotype 95, se-
rotype 1a-serotype 1b, serotype 62-serotype 25, serotype 31-sero-
type 47, serotype 30-serotype 23, serotype 54-serotype 98) that
were less than the maximum recorded intraserotype divergence of
11.4% between two serotype 57 sequences. Similarly, for species
B, the divergence for one pairwise comparison between serotypes
(serotypes 17 and 91; 10.3%) was below the maximum divergence
within a serotype (serotype B52; 10.6%). In many cases, these
different serotype assignments for genetically similar viruses have
been shown to be incorrect (see Discussion).
The distribution of pairwise distances among the data set of
HRV-C sequences was similarly bimodal, with the minimum
value between putative intra- and intertype distances being
approximately 0.1, which corresponds almost exactly to the
thresholds assigned to species A and B (Fig. 3). The pairwise
distances between putative HRV-C types were, however,
greater than those between species A and B variants (mean
value, 27%; mean values for HRV-A and HRV-B, 18% and
20%, respectively). By using the 10% threshold, the pairwise
distances between all available sequences of the HRV-C
strains were assigned to the same and different type categories,
a procedure that produced a total of 47 putative types among
the 227 currently available HRV-C sequences in this region. A
total of 15 different HRV-C types were found among the 33
positive samples identified in the current study, and 2 of these
corresponded to types absent from the larger worldwide col-
lection of HRV-C sequences.
The six remaining samples whose VP4-VP2 regions were
sequenced comprised HEV-B (five samples from four individ-
uals) and HEV-C (one sample). The HEV serotypes were
identified by comparison of the sequences with those of HEV
variants of defined serotype by using the BLAST program.
Two of the species B variants were assigned to coxsackievirus
B type 4 (CVB4) on the basis of their close sequence similarity
(94%) with published sequences of this serotype. For two pos-
itive samples obtained from the same individual, one was
CVB1 (95% similarity) and one was CVB3 (93% similarity);
for the species C variants, the closest matching sequence was
that of CVA21 (92% similarity). All samples positive for HEV
were detected in the September 2006 sampling period.
As a further check of the sensitivity of the combined HRV-
HEV 5 UTR-based method for screening for HEV, all 456
study samples were screened by using the previously described
HEV-specific primers (39). The samples were initially
screened in pools of 10, and positive pools were split to identify
individual positive samples. This procedure identified the same
six samples that were positive by the HEV-HRV screening
assay and no other positive samples.
A small proportion of subjects (n  14) contributed more
than one HRV-positive sample (n  2 to 5) over the study
period. In 10 subjects from whom samples were collected dur-
ing the same month (September 2006 or February 2007), the
VP4-VP2 sequences were closely similar or identical. They
comprised seven samples with HRV-A infections, two samples
with HRV-C infections, and one sample with an HEV infec-
tion. A change in the infecting HRV serotype was observed in
four subjects (HRV-B4 to HRV-A49, NS1 to HRV-A78, NS1
to HRV-A28, HRV-C to HRV-A39), although in the first
three subjects, the change occurred between the two sampling
months. In the final case, the switch from HRV-C to a species
A serotype occurred between samples collected approximately
5 days apart.
Epidemiological and clinical associations of HRV and HEV
infections. HRV-A and HRV-B were substantially more prev-
alent in September than in February (Fig. 4A), differences that
approached or exceeded statistical significance (for species A,
P  0.0009; for species B, P  0.055 [Fisher’s two-tailed exact
test]). By contrast, similar frequencies of species C were found
FIG. 4. Epidemiological characteristics of HRV- and HEV-infected subjects. Frequencies of detection of HRV and HEV in the two sampling
months (proportion of samples) (A), between males and females (proportion of subjects; the sex of one study subject was unknown) (B), and in
different age bands (proportion of subjects) (C) are shown. The y axis depicts the proportion of samples or subjects positive from the total in each
category. m, months.
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between the two sampling months (9/136 samples and 22/320
samples, respectively; P  1.0). HRV-A was the most fre-
quently detected and the most genetically diverse species
found in the study subjects, accounting for 65 of the 104 HRV-
positive samples (63%) whose VP4-VP2 regions could be am-
plified. HRV-C was the second most common (n  31; 30%),
exceeding the incidence of HRV-B by nearly fourfold (n  8).
HRV (and HEV) showed substantial genetic heterogeneity,
with 65 HRV-A-positive samples being classifiable into a total
of 22 different serotypes, 8 HRV-B-positive samples being
classifiable into 6 different serotypes, and 31 HRV-C-positive
samples being classifiable into 15 putatively assigned types
(Table 3). Evidence for the rapid turnover of HRV popula-
tions was provided by the observation of almost entirely dis-
tinct serotype distributions between the two sampling months.
In the case of species A, only 2 of the 11 serotypes detected in
September were found among the 13 serotypes found in Feb-
ruary. For HRV-B and HRV-C, one and two serotypes, re-
spectively, were shared between months.
All three HRV species (and HEV) showed higher frequen-
cies of infection of children, with all infections being largely
confined to those under 10 years of age; and a second peak
occurred in those over 65 years of age (Fig. 4C). Extremely
high infection frequencies were observed in children in the 1-
to 2-year-old age band (60%), whereas none were found in
older children and most adult groups (age range, 16 to 36
years). The relative frequency of detection of HRV-A, -B, and
-C was broadly similar across the age ranges, with HRV-A
being the commonest, followed by species C and then species
B in most age groups; the exception to this finding was the
rarity of HRV-B variants in children less than 1 year of age and
of species C in elderly individuals.
By using the patient, clinical, and other referral information
accompanying the samples, the clinical presentations of indi-
viduals infected with different HRV species and other respira-
tory viruses were compared. Most HRV infections were found
in children under the age of 10 years as monoinfections, with
81%, 80%, and 77% of infections caused by HRV-A, B-, and
-C, respectively, being detected in the absence of coinfection
with other respiratory viruses (RSV, AdV, PIV-1 to PIV-3,
influenza viruses A and B, human metapneumovirus, human
parechovirus). The frequencies of HRV monoinfections were
higher than those observed for other respiratory pathogens,
such as RSV (69%; P  0.1) and AdV (39%; P  0.001). A
significantly higher proportion of females than males were
infected with HRV-C (infection frequencies, 12% and 5%,
respectively; P  0.03 by Fisher’s exact two-tailed test), in
contrast to the slight excess of males infected with HRV-A and
-B (16% for males and 13% for females for HRV-A and 3.2%
for males and 1.9% for females for HRV-B).
HRV infections were detected the most frequently among
those subjects with recorded diagnoses of acute respiratory
tract infections and among those in critical care (including
intensive therapy, high-dependency, and neonatal units), al-
though the frequencies of occurrence of the different HRV
species varied substantially (Fig. 5). Species C infections were
found at nearly twice the frequency of HRV-A and -B infec-
tions (30%, 13.6%, and 14.3%, respectively; P  0.1) among
those with acute respiratory tract infections, with the frequency
of HRV-C infections being similar to the frequencies recorded
for RSV and AdV infections (Fig. 5). In contrast, species A
and B infections were more frequently found in association
with admission to or nursing in a critical care unit (29.5% and
28.6%, respectively), and HRV-C was not detected in that
patient group (P  0.002). This finding is comparable to the
low frequencies of RSV and AdV detection (6.8% and 6.9%,
respectively).
DISCUSSION
This study documents the remarkable diversity and rapid
turnover of HRV variants of all three species at two sample
collection times 5 months apart. Among the respiratory viruses
for which the samples were screened, HRV was by far the most
frequently detected in the study group, being particularly prev-
alent (	50%) among diagnostic specimens collected from chil-
dren between 1 and 2 years of age. Consistent with the findings
of previous studies, variants classifiable as species C were fre-
quently found in respiratory samples (31 of 104; 30%), com-
parable to the frequencies of detection of this species in diag-
nostic respiratory specimens collected worldwide (28% to
52%; [3, 11, 23]) and substantially exceeding the frequency of
detection of HRV-B serotypes. As mentioned previously (20),
it is remarkable how such a prevalent virus infection could
have circulated undetected for so many years, although its lack
of culturability in vitro and the relatively recent application of
PCR-based methods for screening for HRV have undoubtedly
contributed historically to this diagnostic gap.
Assays that screen for HRV typically target the highly con-
FIG. 5. Proportion of subjects under the age of 10 years infected
with HRV-A, HRV-B, HRV-C, RSV, and AdV with recorded symp-
toms or diagnoses of acute respiratory disease or those treated on
critical care wards (intensive therapy, high-dependency, and neonatal
units). The numbers at the tops of the bars are the total number of
subjects in each category; these were used as the denominators to
calculate the HRV detection frequencies (recorded on the y axis).
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served 5 UTR for amplification (5, 9, 10, 27, 38). However, in
addition to detection, identification of the infecting species or
serotype is of key importance diagnostically for the detection
of mixed infections or a reinfection with different HRV sero-
types, as well as in broader clinical investigations of the rela-
tionship between a serotype or species with disease severity
and in epidemiological investigations of the circulation and
turnover of HRVs (20). Unfortunately, the amplicons gener-
ated by most screening assays (including the 5 UTR-based
methods described in this paper) are usually too short and lack
sufficient variability to allow serotypes or, often, species to be
reliably identified (32). Furthermore, while the recombination
events that occur in HRV have not been documented to be as
extensive as those that occur in HEV (14, 25, 30, 33), the 5
UTR-P1 boundary is a recombination hot spot in other picor-
navirus groups and genera. Consequently, phylogeny relation-
ships in the 5 UTR may not reflect those in the structural
gene-coding region on which the serological properties of
HRVs naturally depend. The discordant phylogeny of the 5
UTR sequences from HRV-C epitomizes this problem, with
some variants forming a discrete clade separate from the
clades of species A and B (and enteroviruses) and other vi-
ruses, including the HRV-C prototype sequence, QPM (22),
that falls within species A. This is itself a likely outcome of a
recombination event that occurred in the evolutionary history
of some species C variants.
For these reasons and despite the recent promotion of 5
UTR-based HRV (sero)type identification methods (12, 18),
we concur with Savolainen-Kopra and colleagues that P1-cod-
ing sequences are required for reliable species and serotype
assignments (32). We therefore supplemented our screening
method with a second PCR for typing of VP4-VP2 using
nested primers to ensure reliability and sensitivity for direct
use with clinical specimens. Its ability to amplify and provide
complete amplicon sequences for 109 of the 110 screen-posi-
tive samples (including all 6 of the enterovirus-positive sam-
ples) provided a highly effective tool with which to compare the
genetic diversity, molecular epidemiology, and disease associ-
ations of the three HRV species. A striking finding, mirrored
in other recent PCR-based investigations of rhinovirus diver-
sity (1, 3, 6, 11, 16, 23, 28, 31), was the large number of
circulating types within the study subject population, including
species C. Equally striking was evidence of the rapid turnover
of HRV variants, with only 5 of the 43 HRV-A, -B, and -C
(sero)types being found in both sampling months (Table 3),
findings reminiscent of the detection of multiple HRV sero-
types within the same household over even shorter observation
periods (26).
While comparison of HRV-A and HRV-B VP4-VP2 se-
quences with those of the corresponding region of prototype
strains provides a guide for serotype assignment (14, 25, 29,
36), HRV-C variants are not, to date, formally classified into
types, even though there is equal or greater diversity between
variants in this new clade than in variants in species A or B
(Fig. 1). The lack of in vitro methods of culturing HRV-C
variants would, in any case, preclude the use of the serologi-
cally based typing used for other rhinoviruses, therefore ne-
cessitating (geno)type assignment on the basis of genetic di-
versity. Examination of the distribution of pairwise distances in
VP4-VP2 justifies the placement of a threshold at an uncor-
rected pairwise distance of about 10% for such a purpose and
is similar to the 10% to 11% boundary that divides intra- and
(most) interserotype distances in species A and B in this
genomic region (Fig. 3). By using this provisional type assign-
ment method, the 31 sequences obtained in the current study
combined with the HRV-C variants collected worldwide to
date comprise a total of 47 different types, which is already
more than the number in species B and may, possibly, with
more extensive temporal and geographical sampling, exceed
that in HRV-A.
Reliance on virus isolation techniques may, however, have
also led to long-term underestimates of the extent of HRV-A
and HRV-B serotype diversity. In the case of HRV-A, assign-
ment by similarity values is complicated by the existence of
separately assigned serotypes with similarity values below 11%
that divided interserotype from intraserotype similarity values
in VP4-VP2. In some cases, genetically similar serotypes (be-
low the 10% threshold in VP4-VP2) have been shown to be
serologically cross-reactive (e.g., serotypes A8 and A95 [1%
divergent] [17], serotypes A29 and A44 [5.3%] [4], and sero-
types 1A and 1B [8.3%] [4]), while others (e.g., serotypes A62
and A25 [7.0%] and serotypes A47 and A31 [8.7%]) are ap-
parently non-cross-neutralizable (4). However, in the current
study two HRV-A variants were detected that failed to group
phylogenetically with any prototype strain in either VP4-VP2
or VP1 (Fig. 3) and that showed minimum divergence values
well above the 11% threshold (17.6% and 14.0% for NS1 and
NS2, respectively). Remarkably, comparison of all available
VP4-VP2 sequences from HRV-A revealed the frequent de-
tection of NS1 in Australia (1), Germany (28), the United
States (13), Spain (3), and China (GenBank accession number
EU822866), even though its existence as a likely new serotype
was not specifically commented on in most of those studies.
With the availability of complete genome sequences from all
HRV prototype isolates and the adoption of agreed-upon cri-
teria for the assignment of new HRV types without recourse to
virus isolation, it is likely that the number of HRV (sero- or
geno)types in all three species will greatly expand in the future.
Although it was not the primary focus of the study, the
available clinical and epidemiological information available for
patients in whose samples species and serotype were identified
provided the basis for an initial examination of differences in
the age distributions and clinical presentations of the patients.
The age profiles for infection were similar (Fig. 4C), but there
were substantial differences between HRV-A and -B and
HRV-C in their association with other demographic variables
and clinical presentations. In our study group, there was a
significant overrepresentation of females among those infected
with HRV-C, with the frequency of HRV-C in females being
approximately twice that in males (Fig. 4B). This difference has
not, however, been found in previous comparisons (e.g., 31
females/77 total [23], 14/25 [28], and 7/12 [16]).
We obtained evidence for an association of HRV-C with
more severe primary respiratory infections (Fig. 5) that have
been reported in some previous comparisons (11, 21–23) but
not all previous comparisons (16, 28) of species-associated
differences in the clinical presentations of patients with HRV
infections. The frequencies of symptoms or reported respira-
tory tract disease in patients infected with HRV-C were com-
parable to those in patients infected with RSV and twice those
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in patients infected with species A and B serotypes. These
observations are consistent with the more frequent detection
of this species in children with an underlying severe respiratory
disease, particularly asthma (11, 23) and bronchiolitis, as well
as other lower respiratory tract diseases (16, 21). However,
corroboration of the hypothesis for the greater pathogenicity
of species C will require larger numbers of subjects and a
comparison of HRV species detection frequencies in control
groups of subjects who have mild symptoms or who are non-
symptomatic. The underlying reasons for the high frequency of
subjects with species A and B HRV infections (and the absence
of HRV-C infections) requiring admission to critical care units
remain unclear and need further investigation.
The development of effective methods for HRV detection
and species assignment will, in the future, undoubtedly expand
our knowledge of the role of HRVs in respiratory disease, a
much neglected area of clinical investigation. As discussed
previously (20), HRV may indeed rival or exceed RSV and
other respiratory pathogens in its association with severe dis-
ease requiring hospitalization, as well as in its association with
chronic conditions, such as asthma. The ability of molecular
methods to identify HRV species and serotypes genetically will
additionally allow the heterogeneity in the disease associations
of different HRV variants, including species C variants and the
recently discovered HRV-A types that are perhaps refractory
to conventional virus isolation methods, to be better explored.
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